Pricing Log in Create free account

Caris Life Sciences,�Inc. (CAI) vs Spyre Therapeutics, Inc. (SYRE)

Caris Life Sciences,�Inc. and Spyre Therapeutics, Inc. are both Biotechnology companies. Spyre Therapeutics, Inc. is the larger, with a market value of $9.2B against $7.4B — 1.2× the size. Spyre Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Caris Life Sciences,�Inc. trades at 77.7×. Caris Life Sciences,�Inc. grew revenue faster over the last twelve months: 68.8% against −81.8%. Caris Life Sciences,�Inc. has the higher net margin (9.16% vs 0.00%) and the higher return on invested capital (22.2% vs 0.00%). Across the 16 metrics below, Caris Life Sciences,�Inc. leads on 13 and Spyre Therapeutics, Inc. on 3.

Valuation

Metric CAI SYRE Biotechnology median
P/E 77.71 n/m 10.26
P/S 7.15 8,159.98 9.18
P/B 12.66 9.50 2.05
Price to free cash flow 190.71 n/m 24.81
EV/EBITDA 39.40 n/m 0.65
EV/Sales 6.77 7,142.99 8.98
Earnings yield 1.29% (3.16%) (34.89%)
Free cash flow yield 0.52% (2.89%) (24.52%)

Profitability

Metric CAI SYRE Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 13.35% 0.00% 0.00%
Net margin 9.16% 0.00% 0.00%
Free cash flow margin 8.00% 0.00% 0.00%
Return on equity 0.00% (41.15%) (50.12%)
Return on assets 8.58% (30.89%) (45.60%)
Return on invested capital 22.24% 0.00% 0.00%

Growth

Metric CAI SYRE Biotechnology median
Revenue growth (TTM) 68.84% (81.84%) 6.26%
EPS growth (last fiscal year) 69.79% 55.24% 29.88%
Revenue growth, 5-year CAGR — (28.15%) 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric CAI SYRE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.71 27.40 4.89
Net debt to EBITDA (5.23) 3.61 1.01

Dividend

Metric CAI SYRE Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CAI SYRE Biotechnology median
Market cap 7.36b 9.17b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack